Clinical Trials Logo

Clinical Trial Summary

This an open-label,Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03092895
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Completed
Phase Phase 2
Start date April 27, 2017
Completion date March 31, 2021

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05451290 - Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer Phase 2
Active, not recruiting NCT03704480 - Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. Phase 2
Recruiting NCT05733000 - CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Phase 2
Recruiting NCT04550624 - Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma Phase 2
Recruiting NCT05969860 - At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Phase 2
Completed NCT01828034 - First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma Phase 1/Phase 2